Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific Inc. (NYSE: TMO) files a wide range of documents with the U.S. Securities and Exchange Commission, and this page aggregates those SEC filings for investors tracking TMO. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, and its filings describe the terms, rankings and covenants of these securities, as well as material events affecting the business.
Recent Form 8‑K filings illustrate the types of information Thermo Fisher discloses. Several 8‑Ks detail public offerings of senior notes in U.S. dollars and euros, including maturities, interest payment schedules, redemption provisions, change‑of‑control protections and the use of proceeds for general corporate purposes such as acquisitions, debt repayment or refinancing, working capital, capital expenditures or equity repurchases. Other 8‑Ks report the completion of the acquisition of Solventum Corporation’s purification and filtration business and the signing of a definitive agreement to acquire Clario Holdings, Inc.
Thermo Fisher also uses 8‑K filings to communicate quarterly financial results, leadership transitions and organizational changes. For example, filings describe announcements of financial results for specific fiscal quarters, the planned retirement of the Senior Vice President and Chief Financial Officer and the appointment of a successor, and updates to the organizational structure and leadership team, including changes in executive roles.
On Stock Titan’s SEC filings page for TMO, users can access these current reports alongside other registered securities information, and benefit from AI‑powered summaries that explain key terms, highlight significant covenants, and clarify how new debt offerings, acquisitions, leadership changes or other material events may affect Thermo Fisher Scientific’s capital structure and corporate profile.
Thermo Fisher Scientific reported full-year 2025 revenue of $44.56 billion, up 4%, with GAAP diluted EPS of $17.74 and adjusted EPS of $22.87. GAAP operating income rose to $7.75 billion, and adjusted operating income reached $10.11 billion, with margins improving slightly.
Organic revenue grew 2%, helped by pharma and biotech demand and industrial and applied markets, while academic and government sales declined amid U.S. uncertainty and China macro weakness. Currency translation added $0.37 billion to revenue.
The company continues to operate four major segments and highlights ongoing R&D investment, heavy use of acquisitions, and significant goodwill of $49.36 billion. It ended the year with about $39.38 billion of debt, 371,484,244 shares outstanding and roughly 125,000 employees. A new $5.0 billion repurchase authorization was approved, with $3.0 billion repurchased early in 2026.
Thermo Fisher Scientific Inc. issued four new series of senior unsecured notes totaling $4.8 billion to raise long-term debt capital. The company sold $1.0 billion of 4.215% Notes due 2031, $750 million of 4.550% Notes due 2033, $1.3 billion of 4.902% Notes due 2036 and $750 million of 5.546% Notes due 2046 in a public offering.
Thermo Fisher expects net proceeds of approximately $3.76 billion after underwriting discounts and expenses. It intends to use these funds primarily to pay a portion of the cash consideration for its previously announced acquisition of Clario Holdings, Inc., with any remainder available for general corporate purposes or temporary short-term investments.
The notes include standard optional redemption features before and after defined par call dates, a change-of-control repurchase right at 101% of principal upon specified rating downgrades, and customary covenants limiting secured debt on principal properties, sale-leaseback transactions, and certain mergers or asset sales.
Thermo Fisher Scientific executive vice president Gianluca Pettiti sold 400 shares of common stock in an open-market transaction at $541.20 per share. The sale on February 9, 2026 was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025.
After this transaction, Pettiti directly beneficially owned 20,752.223 shares of Thermo Fisher Scientific common stock. Rule 10b5-1 plans allow insiders to schedule trades in advance, helping separate personal trading decisions from later corporate developments.
Thermo Fisher Scientific is offering $3.8 billion of senior unsecured notes across four tranches: $1.0 billion 4.215% notes due 2031, $750 million 4.550% notes due 2033, $1.3 billion 4.902% notes due 2036 and $750 million 5.546% notes due 2046. The notes price near par, generating gross proceeds of about $3.80 billion and net proceeds of about $3.76 billion after $25.7 million of underwriting discounts and estimated expenses. Thermo Fisher plans to use the cash mainly to fund the pending Clario acquisition, a clinical trial data business valued at $8.875 billion in cash plus up to $525 million of additional consideration. The company reports preliminary 2025 results showing fourth‑quarter revenue up 7% to $12.21 billion and full‑year revenue up 4% to $44.56 billion, with diluted EPS rising to $5.21 for the quarter and $17.74 for the year. The notes include standard investment‑grade style covenants, optional redemption features, and a change‑of‑control repurchase at 101% of principal.
A holder of common stock has filed a Form 144 notice to sell 400 shares. The planned sale is to be executed through Fidelity Brokerage Services LLC on the NYSE around 02/09/2026, with an aggregate market value listed as 216480.00. Shares outstanding are shown as 375,708,059, giving a sense of the company’s overall size.
The 400 shares to be sold were acquired on 02/28/2024 via restricted stock vesting from the issuer as compensation. The filing also notes that Gianluca Pettiti, at the same address, sold 2,975 common shares on 11/10/2025 for gross proceeds of 1725500.00 during the past three months.
Thermo Fisher Scientific Inc. is launching a multi‑tranche senior notes offering of unsecured senior debt, with each series paying semiannual interest and featuring optional redemption and change‑of‑control repurchase protections. The notes rank equally with other unsecured senior debt and are structurally subordinated to subsidiary obligations.
Thermo Fisher plans to use the net proceeds primarily to fund the cash portion of its pending Clario Holdings acquisition, with any remainder available for general corporate purposes, including other acquisitions, debt repayment, capital spending or share repurchases. The company also reports preliminary 2025 results showing fourth‑quarter revenue of $12.21 billion versus $11.40 billion and diluted EPS of $5.21 versus $4.78, with full‑year revenue of $44.56 billion versus $42.88 billion and EPS of $17.74 versus $16.53.
Thermo Fisher Scientific Inc. furnished an update on its business by announcing financial results for the fiscal quarter and full year ended December 31, 2025. The company released these results through a press release dated January 29, 2026.
The press release containing the detailed quarterly and annual financial information is provided as Exhibit 99.1. This information is treated as "furnished" rather than "filed" under the Securities Exchange Act of 1934, which limits how it is incorporated into other regulatory documents.
Thermo Fisher Scientific Inc. filed a Form 25 to remove its 1.400% Senior Notes due 2026 from listing and registration on the New York Stock Exchange. The exchange states it has followed its own rules to strike this class of debt securities from listing and/or withdraw their registration, and the issuer has complied with the exchange’s procedures and the related SEC requirements for voluntary withdrawal.
Thermo Fisher Scientific Inc. has had its 3.200% Senior Notes due 2026 removed from listing and registration on the New York Stock Exchange LLC. The Exchange certified that it complied with its own rules to strike this class of securities from listing and/or withdraw their registration, and the issuer complied with the Exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) for voluntary withdrawal. This action applies specifically to the 3.200% Senior Notes due 2026 and does not describe any change to the company’s other listed securities.
Thermo Fisher Scientific Inc. reported upcoming leadership changes following the planned departures of two senior executives. Executive Vice President and Chief Operating Officer Michel Lagarde, who has held the COO role since 2021, will leave the company on March 31, 2026. Executive Vice President Frederick M. Lowery, in that role since 2024, will depart on February 28, 2026.
Effective March 1, 2026, the company will update its organizational structure. Marc N. Casper will serve as Chairman and Chief Executive Officer. Gianluca Pettiti, currently an Executive Vice President, will be promoted to President and Chief Operating Officer, while Michael Shafer, also an Executive Vice President, will move into an expanded role reporting directly to the Chief Executive Officer. These changes outline Thermo Fisher’s succession and leadership realignment plan at the top of the organization.